Ipsen stock

IPN · Euronext Paris · EUR

Compare Ipsen
€161.60Change from previous close: −0.49%Absolute change: −€0.80

Close · November 20, 2026

Price history

+27.34% over the period

1 year: from €126.90 (November 20, 2025) to €161.60 (November 20, 2026), +27.34%.

Show chart data

Closing prices adjusted for splits: the last close of each month.

DateClose
November 20, 2026€161.60
October 30, 2026€157.60
September 30, 2026€142.10
August 31, 2026€163.10
July 31, 2026€167.20
June 30, 2026€168.80
May 29, 2026€156.60
April 30, 2026€167.00
March 31, 2026€160.40
February 27, 2026€165.10
January 30, 2026€137.60
December 31, 2025€119.00
November 28, 2025€124.30
November 20, 2025€126.90

At a glance

  • The company

    Biopharmaceutical company developing and commercializing medicines in oncology, rare diseases, and neuroscience across multiple markets

  • Latest results

    Quarter to September 30, 2026

TickerLandia's take on Ipsen

Analysis calculated by TickerLandia from financial statements and prices, with public rules. Not investment advice. How we analyse stocks

Where the price stands

52-wk low€115.60
52-wk high€174.00

−7.13% from the 52-week high

Analysts · 13 analysts

Average target€162.23+0.39% vs. price

Buy 4 · Hold 6 · Sell 3 · Hold

TickerLandia Fingerprint: Ipsen

Compared with similar companies: low risk, strong momentum, and low price.

Financials and price compared with 39 companies in the drug manufacturers - specialty & generic industry, worldwide. Momentum and risk compared with 1,160 European stocks.

Position in the group from 0 to 100 (100 = highest value): it describes, it does not rate. Tap a row for the metrics. Calculated on November 22, 2026. An indicator calculated by TickerLandia from financial statements and market data. How it is calculated

Valuation

Ipsen is pricier than in the past and pricier than similar companies

On the latest fiscal year's earnings (2025), Ipsen's P/E today is 30.4, above the median of its last 9 fiscal years (22.4; between 10.3 and 30.6 from 2016 to 2025). Ipsen's P/E (trailing 12 months): 26.1, +7% against the median of a group of 11 similar companies (24.5).

P/E compared with its history

Compared with 11 similar companies

Ipsen's metrics compared with similar companies
MetricIpsenPosition in the groupBand
P/E (trailing 12 months)26.1Middle
Forward P/E11.2Low
Operating margin27.4%High
ROE11.4%Middle
Debt/equity0.20Low

P/E at fiscal year end; today on the latest fiscal year's earnings. Grey band: the middle half of the group; tick: the median; dot: Ipsen. All multiples and dividends

TickerLandia analysisHow it is calculated

The financials

The business in numbers

Revenue

€2.3B

Latest quarter · Q2 2026

Net income

€403.1M

Latest quarter · Q2 2026

Quarterly net margin

17.5%

Latest quarter · Q2 2026

Numbers and valuation

Full valuation
Market cap
€13.31B
P/E
26.1
EPS
€6.18
Volume
23.16K
Daily trading
€16.5M
Dividend yield
0.99%
Last ex-dividend on June 3, 2026

How Ipsen is changing

All results
  • Revenue grew 7.9% a year on average over the last 5 years

  • Operating margin fell from 29.9% to 26.1%

  • Profits turn into cash: free cash flow equal to 176% of net income

Returns

Ipsen returns with dividends

€1,000 invested in Ipsen 5 years ago, on November 22, 2021, would be worth €1,905 today with dividends reinvested: +90.50% in total, +13.78% per year. On price alone it would be €1,799 (+79.88%).

PeriodIpsenCAC 40€1,000 becomes
1 month+6.39%+1.14%€1,064
6 months+1.25%−2.34%€1,013
Year to date+35.80%−2.72%€1,358
1 year+28.69%−0.67%€1,287
3 years+60.58%+9.39%€1,606
5 years+90.50%+11.58%€1,905
10 years+185.62%+75.02%€2,856

Over the last 6 months it has done better than 27% of the stocks in the Healthcare sector.

From 1 year up with dividends reinvested, before taxes; under a year price only. CAC 40: price only. Calculate your investment

The chart in detail

Ipsen: technical analysis

Ipsen shows no clear trend: the price and its 50- and 200-session averages are not aligned. The price is 6.5% below its all-time closing high (€172.90, May 6, 2026).

Trend
No clear trend
RSI (14 sessions)
56
Between 30 and 70
vs 200-session average
+1.91%

Support and resistance

Price areas where Ipsen has stopped several times in the last year. They describe the chart; they are not forecasts.

  1. Resistance€173.40+7.30%3 touches, last on July 31, 2026
  2. Resistance€170.60+5.57%3 touches, last on November 12, 2026
  3. Last price€161.60
  4. Support€158.90−1.67%3 touches, last on June 8, 2026
  5. Support€155.90−3.53%2 touches, last on July 24, 2026
  6. Support€152.93−5.36%3 touches, last on August 12, 2026

Volatility and risk

Over the last year it has moved little with the CAC 40.

Beta (1 year) vs CAC 40
0.32
Volatility (60 sessions, annualised)
25.4%
Largest fall in the last year
−19.26%

Close of November 20, 2026. Descriptive data calculated on daily prices: it describes the chart and is not investment advice. Beta and volatility describe the last year and can change a lot from one year to the next. How we calculate it

Ipsen: seasonality

Average monthly price change over 21 years

+1.8%Jan+3.0%Feb+0.3%Mar+5.5%Apr+2.1%May−2.9%Jun+1.4%Jul+1.9%Aug−1.0%Sep+1.1%Oct+0.1%Nov−0.1%Dec

Over the last 21 years, the strongest month for Ipsen has been April: +5.51% on average, positive in 15 years out of 21. The weakest has been June: −2.94% on average, positive in 8 years out of 21. November, the current month, has been positive in 11 years out of 20 (+0.10% on average).

Show chart data
MonthAverageMedianPositive years
January+1.75%+4.37%12 of 21
February+3.03%+0.03%11 of 21
March+0.33%+0.49%11 of 21
April+5.51%+5.93%15 of 21
May+2.06%+2.69%15 of 21
June−2.94%−2.51%8 of 21
July+1.44%+2.57%14 of 21
August+1.89%+3.12%12 of 21
September−1.00%−0.35%9 of 21
October+1.05%+3.65%14 of 21
November+0.10%+1.81%11 of 20
December−0.11%+1.22%11 of 20

Price change only, dividends excluded. Past seasonality does not predict future moves.

The company

Ipsen and its competitors

Ipsen is best known for Somatuline, Dysport and Decapeptyl, with Cabometyx, Onivyde, Bylvay, Iqirvo and Sohonos also among its marketed or developed medicines. The biopharmaceutical group develops and commercializes treatments in oncology, rare disease and neuroscience, selling them in North America, Europe and other international markets. Its pipeline includes candidates in Phase III trials for follicular lymphoma and pediatric low-grade gliomas, as well as earlier-stage programs in solid tumors and aesthetic indications.

Headquarters
Paris, France
Employees
5,535
Founded
1929
Chief executive
David Loew
Ipsen and its competitors
CompanyMarket capOperating marginP/E (trailing 12 months)6 months
IpsenIPN$14.63B27.4%26.1+1.25%
Swedish Orphan BiovitrumSOBI$15.83B30.9%24.5+6.32%
H. LundbeckHLUN.A$8.56B24.4%14.4+63.06%
HaleonHLN$39.73B23.5%19.2+1.20%
Sandoz GroupSDZ$41.51B9.3%68.8+22.19%
Galderma GroupGALD$50.81B19.1%63.1+14.60%

Same industry or related industries, similar size. Compare Ipsen with its competitors · Full profile